<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id>
      <journal-id journal-id-type="publisher-id">JKMS</journal-id>
      <journal-title-group>
        <journal-title>Journal of Korean Medical Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1011-8934</issn>
      <issn pub-type="epub">1598-6357</issn>
      <publisher>
        <publisher-name>The Korean Academy of Medical Sciences</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17043436</article-id>
      <article-id pub-id-type="pmc">2722012</article-id>
      <article-id pub-id-type="doi">10.3346/jkms.2006.21.5.946</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Etanercept-Induced Systemic Lupus Erythematosus in a Patient with Rheumatoid Arthritis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kang</surname>
            <given-names>Min-Jung</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
          <xref ref-type="author-notes" rid="FN1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>You-Hyun</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
          <xref ref-type="author-notes" rid="FN1">*</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lee</surname>
            <given-names>Jisoo</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
      </contrib-group>
      <aff id="A1">Department of Internal Medicine, Division of Rheumatology Ewha Womans University College of Medicine, Seoul, Korea.</aff>
      <author-notes>
        <corresp>Address for correspondence: Jisoo Lee, M.D. Department of Internal Medicine, Ewha Womans University College of Medicine, 911-1 Mok-dong, Yangcheon-gu, Seoul 158-710, Korea. Tel: +82.2-2650-6164, Fax: +82.2-2655-2076, <email>leejisoo@ewha.ac.kr</email></corresp>
        <fn id="FN1" fn-type="equal">
          <p><sup>*</sup>equal contribution by both authors</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>10</month>
        <year>2006</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>10</month>
        <year>2006</year>
      </pub-date>
      <volume>21</volume>
      <issue>5</issue>
      <fpage>946</fpage>
      <lpage>949</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>4</month>
          <year>2005</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>8</month>
          <year>2005</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2006 The Korean Academy of Medical Sciences</copyright-statement>
        <copyright-year>2006</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Tumor necrosis factor (TNF) is known to play a critical role in the pathogenesis of rheumatoid arthritis (RA). Etanercept is a recombinant soluble fusion protein of TNF&#x3B1; type II receptor and IgG, which acts as a specific TNF-&#x3B1; antagonist. Anti-TNF-&#x3B1; therapy has been an important advance in the treatment of RA. However, induction of autoantibodies in some proportion of patients treated with TNF&#x3B1; inhibitors raised concerns for development of systemic autoimmune diseases such as systemic lupus erythematosus (SLE). Although new autoantibody formation is common with anti-TNF&#x3B1; therapy, there are only rare reports of overt SLE, most of which manifested without major organ involvement and resolved shortly after discontinuation of the therapy. We describe a 55-yr-old Korean woman who developed overt life threatening SLE complicated by pneumonia and tuberculosis following etanercept treatment for RA. This case is to our knowledge, the first report of etanercept-induced SLE in Korea.</p>
      </abstract>
      <kwd-group>
        <kwd>Lupus Erythematosus, Systemic</kwd>
        <kwd>Etanercept</kwd>
        <kwd>TNFR-Fc fusion protein</kwd>
        <kwd>Arthritis, Rheumatoid</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Etanercept is a soluble tumor necrosis factor (TNF&#x3B1;) receptor fusion protein, which inhibits the biological activity of TNF&#x3B1;. Specific therapy targeting TNF&#x3B1; has been offered an important advance in the treatment of active rheumatoid arthritis (RA) (<xref ref-type="bibr" rid="B1">1</xref>). Although anti-inflammatory and disease-modifying effect of anti-TNF&#x3B1; therapy are well known, there are concerns for development of serious side effects such as autoimmune disorder, infection and neoplasm as the physiologic actions of TNF&#x3B1; are blocked (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>).</p>
      <p>Drug-induced lupus was firstly reported by Hoffman in 1945, in a patient who developed hypersensitivity syndrome similar to acute systemic lupus erythematosus (SLE) after taking sulfadiazine (<xref ref-type="bibr" rid="B4">4</xref>). Up to 80 kinds of drugs have been known to induce lupus-like syndrome, composing approximately 10% of the all SLE cases (<xref ref-type="bibr" rid="B5">5</xref>). Anti-TNF&#x3B1; agents including etanercept have recently been considered as drugs that can potentially induce lupus, since new autoantibodies such as antinuclear antibodies (ANAs) and anti-double stranded DNA (anti-dsDNA) antibodies were detected in anti-TNF&#x3B1; treated patients (<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>).</p>
      <p>Shakoor et al. described the first SLE case among the RA patients treated with etanercept in 2002 (<xref ref-type="bibr" rid="B9">9</xref>). Since then, a few similar cases have been reported, that alarmed the clinicians for development of SLE in RA patients treated with anti-TNF&#x3B1; agents (<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B13">13</xref>). However, all of the reported cases of anti-TNF&#x3B1;-induced SLE was manifested without major organ involvement and resolved shortly after the discontinuation of the therapy. Although a case of tuberculous pleurisy following infliximab therapy was reported in Korea, etanercept associated SLE was not reported previously (<xref ref-type="bibr" rid="B14">14</xref>). Herein, we describe a 55-yr-old Korean woman who developed overt life threatening SLE complicated by pneumonia and tuberculosis following etanercept treatment for RA.</p>
    </sec>
    <sec sec-type="cases">
      <title>CASE REPORT</title>
      <p>A 55-yr-old Korean woman presented with fever and generalized weakness which persisted for 3 months. She had no history of pulmonary tuberculosis or diabetes mellitus. She was diagnosed as seropositive RA 20 yr ago, and had been treated with prednisolone, NSAIDs and methotrexate. Since she had continued active joint inflammation, 25 mg of etanercept twice weekly subcutaneous injection was added to the treatment 8 months ago. Despite improvement of her arthritic symptoms, she began to experience severe fatigue and malaise 3 months ago. Intermittent high fever, myalgia, oral ulcers, gum bleeding, and 10 kg-weight loss were associated. Physical examination revealed cachexic, chronic ill looking woman with severe wasting. Her blood pressure was 130/75 mmHg, heart rate 88/min, and body temperature 38.1&#x2103;. Her hands demonstrated typical changes of RA with ulnar deviation and deformity of her fingers. Conjunctiva was anemic. Shallow irregular shaped ulcers with hemorrhagic spots were noted in the oral cavity. On chest examination, crackles were heard over both lung fields. There was no abnormal finding without hepatosplenomegaly in the abdomen. Initial complete blood count revealed hemoglobin of 7.7 g/dL, white cell count of 3,000/&#xB5;L (65% neutrophil, 26% lymphocyte), and platelet of 40,000/&#xB5;L. Peripheral blood smear showed no abnormal hematologic cells. Erythrocyte sedimentation rate was 11 mm/hr and C-reactive protein was positive at 0.6 mg/dL (normal &lt;0.3). Blood chemistry values revealed a total protein of 6.6 g/dL, albumin of 2.4 g/dL, BUN 17 mg/dL, creatinine 0.6 mg/dL, AST 447 IU/L, and ALT 113 IU/L. Creatine kinase was elevated to 253 IU/L. Urinalysis revealed one positive for protein. ANA was positive at a titer of 1:640, staining speckled pattern, and rheumatoid factor was positive at 2,180 IU/mL (normal &lt;15 IU/mL). Anti-dsDNA was positive at 14.2 IU/mL (normal &lt;10 IU/mL). Antibodies against ribonucleoprotein and Ro/SS-A were positive, but La/SS-B and Smith were negative. C3 was 19.2 mg/dL, C4 was 9.9 mg/dL. Symmetrically narrowed joint spaces, bony erosion, and osteopenia were shown in hand radiography suggesting chronic RA with destructive change. Chest radiography revealed pneumonia and pulmonary edema in both lung field (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Chest CT showed pneumonia, pulmonary edema, and pleural effusion with pulmonary hemorrhage suggestive of lupus pneumonitis (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Bone marrow examination was normal except for increased megakaryocyte without evidence of hematologic malignancies.</p>
      <p>A diagnosis of SLE with major organ involvement with pneumonitis and thrombocytopenia was made. Etanercept was discontinued and high dose corticosteroid was started. Lupus pneumonitis complicated with pulmonary hemorrhage was improved with corticosteroids treatment. However, residual lung infiltration remained. Bronchoscopic cell culture and PCR of sputum revealed coexistent adenoviral infection, and acyclovir was instituted. Two month later, her general condition markedly improved. However, she was complicated by unilateral pleural effusion, which showed positive for acid-fast bacilli PCR. Anti-tuberculous therapy of isoniazid, ethambutol, rifampin, and pyrazinamide was started. She is maintained on prednisolone 20 mg/day, hydroxychloroquine 300 mg/day, and nabumetone 1 g/day with minimal symptoms upon 12 months of follow up. However, she still had high titers of ANA and anti-dsDNA antibodies.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>TNF&#x3B1; is an important pro-inflammatory cytokine that can cause inflammation and bony erosion in RA. TNF&#x3B1; inhibitors, such as infliximab, etanercept, and adalimumab were shown to be very effective in reducing synovial inflammation and retarding structural damage in RA patients. Anti-TNF&#x3B1; therapy has opened a new era in treatment of RA, and is being used more and more in current rheumatologic practice. Although TNF&#x3B1; inhibitors are effective therapy for RA, the concerns for serious side effects have been also raised. Adverse events that can potentially occur in anti-TNF&#x3B1; treated patients include tuberculosis, bacterial sepsis, heart failure, hematologic malignancy, and systemic autoimmune disease such as SLE and systemic sclerosis (<xref ref-type="bibr" rid="B15">15</xref>).</p>
      <p>Autoantibody formation was reported at high frequency in anti-TNF&#x3B1; treated patients. In RA patients treated with infliximab, ANA developed in 29-76.7% and anti-dsDNA in 10-29% (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). Also in etanercept treated RA patients, 11-36.3% patients had developed ANA, and 5-15% developed anti-dsDNA (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>). In Crohn's disease, autoantibody development and infliximab-induced SLE were reported (<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B24">24</xref>). Shakoor et al. first reported four cases of etanercept-induced SLE in a series of RA patients in 2002 (<xref ref-type="bibr" rid="B9">9</xref>). Swale et al. also reported a case of SLE following 12 months of etanercept therapy in the following year (<xref ref-type="bibr" rid="B10">10</xref>). In the previous reports, timing of the onset and offset of the SLE features strongly supported a drug related effect of etanercept. In these patients, SLE developed after mean 7.7 months (range 3-24) of commencing etanercept therapy, and were all women. Most common clinical feature of SLE was skin rash. There was no significant life threatening organ involvement such as kidney, lung, heart and central nervous system. The SLE features were resolved rapidly on stopping the treatment. The British Society for Rheumatology recommends stopping anti-TNF&#x3B1; therapy and appropriate treatment if symptoms of an SLE-like syndrome develop on anti-TNF&#x3B1; treatment (<xref ref-type="bibr" rid="B25">25</xref>).</p>
      <p>The pathogenesis of anti-TNF&#x3B1; in development of SLE has not been yet clarified. Cairns et al. explained that TNF&#x3B1; may up-regulate the cellular expression of the adhesion molecule CD44, which has a role in the clearance of apoptotic neutrophil by phagocyte. Reduced CD44 expression by anti-TNF&#x3B1; can potentially induce SLE by abnormal clearance and exposure to apoptotic materials (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B26">26</xref>). Long term exposure over 30 weeks to infliximab has been suggested as a factor that can lead to SLE in one study (<xref ref-type="bibr" rid="B17">17</xref>). Although autoantibody formation is quite prevalent in anti-TNF&#x3B1; treated patients, overt clinical syndrome of SLE is rare, suggesting development of SLE in patients treated with anti-TNF&#x3B1; have certain genetic or environmental factors predisposing for systemic autoimmune diseases.</p>
      <p>As in our case, severe life-threatening SLE with major organ involvement can occur after etanercept therapy. Risk factors for development of systemic autoimmune diseases should also be evaluated before starting anti-TNF&#x3B1; therapy, as screening for tuberculosis recommended before anti-TNF&#x3B1; treatment.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olsen</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>New drugs for rheumatoid arthritis</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>2167</fpage>
          <lpage>2179</lpage>
          <pub-id pub-id-type="pmid">15152062</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roberts</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mccoll</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis</article-title>
          <source>Intern Med J</source>
          <year>2004</year>
          <volume>34</volume>
          <fpage>687</fpage>
          <lpage>693</lpage>
          <pub-id pub-id-type="pmid">15610214</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>TY</given-names>
            </name>
            <name>
              <surname>Joung</surname>
              <given-names>CI</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Uhm</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Jun</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Bae</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>The efficacy and safety of etanercept in patients with active rheumatoid arthritis receiving methotrexate</article-title>
          <source>Korean J Med</source>
          <year>2004</year>
          <volume>66</volume>
          <fpage>513</fpage>
          <lpage>520</lpage>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoffman</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus</article-title>
          <source>Arch Dermatol Syphilis</source>
          <year>1945</year>
          <volume>51</volume>
          <fpage>190</fpage>
          <lpage>192</lpage>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antonov</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kazandjieva</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Etugov</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gospodinov</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tsankov</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced lupus erythematosus</article-title>
          <source>Clin Dermatol</source>
          <year>2004</year>
          <volume>22</volume>
          <fpage>157</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="pmid">15234017</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pisetsky</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor &#x3B1; blockers and the induction of anti-DNA autoantibodies</article-title>
          <source>Arthritis Rheum</source>
          <year>2000</year>
          <volume>43</volume>
          <fpage>2381</fpage>
          <lpage>2382</lpage>
          <pub-id pub-id-type="pmid">11083257</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Charles</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Smeenk</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>De Jong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Feldmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maini</surname>
              <given-names>RN</given-names>
            </name>
          </person-group>
          <article-title>Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor &#x3B1;</article-title>
          <source>Arthritis Rheum</source>
          <year>2000</year>
          <volume>43</volume>
          <fpage>2383</fpage>
          <lpage>2390</lpage>
          <pub-id pub-id-type="pmid">11083258</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eriksson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Engstrand</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sundqvist</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Rantap&#xE4;&#xE4;-Dahlqvist</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF&#x3B1;</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <fpage>403</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="pmid">15297281</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shakoor</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Michalska</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Block</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced systemic lupus eythematosus associated with etanercept therapy</article-title>
          <source>Lancet</source>
          <year>2002</year>
          <volume>359</volume>
          <fpage>579</fpage>
          <lpage>580</lpage>
          <pub-id pub-id-type="pmid">11867114</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swale</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Perrett</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Denton</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Rustin</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Etanercept-induced systemic lupus erythematosus</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2003</year>
          <volume>28</volume>
          <fpage>604</fpage>
          <lpage>607</lpage>
          <pub-id pub-id-type="pmid">14616825</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rothfield</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis</article-title>
          <source>Arthritis Rheum</source>
          <year>2003</year>
          <volume>48</volume>
          <fpage>1165</fpage>
          <lpage>1166</lpage>
          <pub-id pub-id-type="pmid">12687569</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cairns</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Hinder</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Taggart</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2002</year>
          <volume>61</volume>
          <fpage>1031</fpage>
          <lpage>1032</lpage>
          <pub-id pub-id-type="pmid">12379532</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Debandt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vittecoq</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Descamps</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Le L&#xF6;et</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Anti-TNF-&#x3B1;-induced systemic lupus syndrome</article-title>
          <source>Clin Rheumatol</source>
          <year>2003</year>
          <volume>22</volume>
          <fpage>56</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">12605321</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Seo</surname>
              <given-names>YI</given-names>
            </name>
            <name>
              <surname>Eom</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>KS</given-names>
            </name>
          </person-group>
          <article-title>Occurrence of tuberculous pleurisy associated with infliximab therapy</article-title>
          <source>Korean J Med</source>
          <year>2004</year>
          <volume>67</volume>
          <fpage>421</fpage>
          <lpage>424</lpage>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Via</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Shustov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rus</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Finkelman</surname>
              <given-names>FD</given-names>
            </name>
          </person-group>
          <article-title>In vivo neutralization of TNF-&#x3B1; promotes humoral autoimmunity by preventing the induction of CTL</article-title>
          <source>J Immunol</source>
          <year>2001</year>
          <volume>167</volume>
          <fpage>6821</fpage>
          <lpage>6826</lpage>
          <pub-id pub-id-type="pmid">11739498</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caramaschi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Biasi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Colombatti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pieropan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Martinelli</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Carletto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Volpe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pacor</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Bambara</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Anti-TNF&#x3B1; therapy in rheumatoid arthritis and autoimmunity</article-title>
          <source>Rheumatol Int</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>209</fpage>
          <lpage>214</lpage>
          <pub-id pub-id-type="pmid">15627197</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bobbio-Pallacini</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Claudia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Caporali</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Avalle</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bugatti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Montecucco</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment</article-title>
          <source>Arthritis Res Ther</source>
          <year>2004</year>
          <volume>6</volume>
          <fpage>264</fpage>
          <lpage>271</lpage>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinblatt</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Kremer</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Bankhurst</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Bulpitt</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Fleischmann</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Burge</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate</article-title>
          <source>N Engl J Med</source>
          <year>1999</year>
          <volume>340</volume>
          <fpage>253</fpage>
          <lpage>259</lpage>
          <pub-id pub-id-type="pmid">9920948</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreland</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Schiff</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Baumgartner</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Tindall</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Fleischmann</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Bulpitt</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Weaver</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Keystone</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Furst</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Ruderman</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Arkfeld</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Garrison</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Burge</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Blosch</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>McDonnell</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Weinblatt</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Etanercept therapy in rheumatoid arthritis</article-title>
          <source>Ann Intern Med</source>
          <year>1999</year>
          <volume>130</volume>
          <fpage>478</fpage>
          <lpage>486</lpage>
          <pub-id pub-id-type="pmid">10075615</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klapman</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Ene-Stroescu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Hanauer</surname>
              <given-names>SB</given-names>
            </name>
          </person-group>
          <article-title>A lupus-like syndrome associated with infliximab therapy</article-title>
          <source>Inflam Bowel Dis</source>
          <year>2003</year>
          <volume>9</volume>
          <fpage>176</fpage>
          <lpage>178</lpage>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarzi-Puttini</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ardizzone</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Manzionna</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Atzeni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Colombo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Antivalle</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carrabba</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bianchi-Porro</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Infliximab-induced lupus in Crohn's disease: a case report</article-title>
          <source>Dig Liver Dis</source>
          <year>2003</year>
          <volume>35</volume>
          <fpage>814</fpage>
          <lpage>817</lpage>
          <pub-id pub-id-type="pmid">14674674</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ali</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Infliximab-induced systemic lupus erythematosus</article-title>
          <source>Ann Intern Med</source>
          <year>2002</year>
          <volume>137</volume>
          <fpage>625</fpage>
          <lpage>626</lpage>
          <pub-id pub-id-type="pmid">12353965</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia-Planella</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dom&#xE8;nech</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Esteve-Comas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bernal</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Cabr&#xE9;</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Boix</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gassull</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF&#x3B1; antibodies (infliximab)</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>2003</year>
          <volume>15</volume>
          <fpage>351</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="pmid">12655253</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vermeire</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Noman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Van Assche</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Baert</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Van Steen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Esters</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Joossens</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bossuyt</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Rutgeerts</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study</article-title>
          <source>Gastroenterology</source>
          <year>2003</year>
          <volume>125</volume>
          <fpage>32</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="pmid">12851868</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ledingham</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Deighton</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <collab>British Society for Rheumatology Standards, Guidelines and Audit Working Group (SGAWG)</collab>
          <article-title>Update on the British Society for Rheumatology guidelines for prescribing TNF-&#x3B1; blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)</article-title>
          <source>Rheumatology</source>
          <year>2005</year>
          <volume>44</volume>
          <fpage>157</fpage>
          <lpage>163</lpage>
          <pub-id pub-id-type="pmid">15637039</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hart</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Dougherty</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Haslett</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dransfield</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages</article-title>
          <source>J Immunol</source>
          <year>1997</year>
          <volume>159</volume>
          <fpage>919</fpage>
          <lpage>925</lpage>
          <pub-id pub-id-type="pmid">9218612</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Chest radiography shows pneumonic consolidation and pulmonary edema in both lung fields</p>
      </caption>
      <graphic xlink:href="jkms-21-946-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Fig. 2</label>
      <caption>
        <p>Chest CT shows pneumonic consolidation, pulmonary edema, and pleural effusion or possible pulmonary hemorrhage.</p>
      </caption>
      <graphic xlink:href="jkms-21-946-g002"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
